Brief: Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown In Its Artistry-1 Clinical Trial Of Nemvaleukin
20/11/2024 22:21
Nov 20 (Reuters) - Mural Oncology PLC MURA.O :
* MURAL ONCOLOGY ANNOUNCES PUBLICATION HIGHLIGHTING
PROMISING
CLINICAL ANTITUMOR ACTIVITY SHOWN IN ITS ARTISTRY-1 CLINICAL
TRIAL OF NEMVALEUKIN, ITS LEAD ENGINEERED FUSION PROTEIN, IN THE
JOURNAL FOR IMMUNOTHERAPY OF CANCER
Source text: ID:nGNX1c1yP2
Further company coverage: MURA.O
Recent news on Mural Oncology
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM